Commit and Osmolar gap abnormal - a phase IV clinical study of FDA data
Summary:
We study 4,910 people who take Commit (nicotine polacrilex) or have Osmolar gap abnormal. No report of Osmolar gap abnormal is found in people who take Commit.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Commit?
Commit has active ingredients of nicotine polacrilex. eHealthMe is studying from 4,842 Commit users. Check the latest studies of Commit.
What is Osmolar Gap Abnormal?
Osmolar gap abnormal is found to be associated with 22 drugs and 14 conditions by eHealthMe. Check the latest studies of Osmolar gap abnormal.
No report is found.
Do you take Commit and have Osmolar gap abnormal?
- Check whether Osmolar gap abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Commit:
- Commit (4,842 reports)
Osmolar gap abnormal treatments and more:
- Osmolar gap abnormal (68 reports)
How severe was Osmolar gap abnormal and when was it recovered:
Expand to all the drugs that have ingredients of nicotine polacrilex:
Browse all side effects of Commit:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Osmolar gap abnormal:
Browse all the conditions that are associated with Osmolar gap abnormal:
How the study uses the data?
The study uses data from the FDA. It is based on nicotine polacrilex (the active ingredients of Commit) and Commit (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Gout Aggravated and Malaise - 3 seconds ago
- Could Wellbutrin cause Burning Sensation? - 6 seconds ago
- Could Macrobid cause Feeling Hot? - 20 seconds ago
- Could Adderall cause Cachexia? - 20 seconds ago
- Acyclovir and Zovirax drug interactions for men aged 60+ - 29 seconds ago
- Hydrochlorothiazide vs. Minoxidil, side effect and effectiveness comparison - 33 seconds ago
- How effective is Baclofen for Relapsing-Remitting Multiple Sclerosis? - 36 seconds ago
- Could Nisoldipine cause Chest Pain? - 45 seconds ago
- Drug interactions of Prandin and Salagen - 58 seconds ago
- Drug interactions of Lansoprazole and Paricalcitol - a minute ago